Logo image of ENSC

ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis

USA - NASDAQ:ENSC - US2936025046 - Common Stock

2.47 USD
+0.15 (+6.47%)
Last: 10/14/2025, 8:00:02 PM
2.48 USD
+0.01 (+0.4%)
After Hours: 10/14/2025, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, ENSC scores 4 out of 10 in our fundamental rating. ENSC was compared to 536 industry peers in the Biotechnology industry. While ENSC seems to be doing ok healthwise, there are quite some concerns on its profitability. ENSC is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENSC had negative earnings in the past year.
In the past year ENSC has reported a negative cash flow from operations.
In the past 5 years ENSC reported 4 times negative net income.
ENSC had a negative operating cash flow in each of the past 5 years.
ENSC Yearly Net Income VS EBIT VS OCF VS FCFENSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

ENSC's Return On Assets of -118.07% is on the low side compared to the rest of the industry. ENSC is outperformed by 79.10% of its industry peers.
The Return On Equity of ENSC (-194.20%) is worse than 66.98% of its industry peers.
Industry RankSector Rank
ROA -118.07%
ROE -194.2%
ROIC N/A
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENSC Yearly ROA, ROE, ROICENSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENSC Yearly Profit, Operating, Gross MarginsENSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ENSC has been increased compared to 1 year ago.
Compared to 5 years ago, ENSC has less shares outstanding
Compared to 1 year ago, ENSC has an improved debt to assets ratio.
ENSC Yearly Shares OutstandingENSC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENSC Yearly Total Debt VS Total AssetsENSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -33.58, we must say that ENSC is in the distress zone and has some risk of bankruptcy.
ENSC's Altman-Z score of -33.58 is on the low side compared to the rest of the industry. ENSC is outperformed by 90.49% of its industry peers.
ENSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.58
ROIC/WACCN/A
WACCN/A
ENSC Yearly LT Debt VS Equity VS FCFENSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ENSC has a Current Ratio of 2.10. This indicates that ENSC is financially healthy and has no problem in meeting its short term obligations.
ENSC has a Current ratio of 2.10. This is in the lower half of the industry: ENSC underperforms 73.32% of its industry peers.
ENSC has a Quick Ratio of 2.10. This indicates that ENSC is financially healthy and has no problem in meeting its short term obligations.
ENSC has a worse Quick ratio (2.10) than 71.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2.1
Quick Ratio 2.1
ENSC Yearly Current Assets VS Current LiabilitesENSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 91.07% over the past year.
Looking at the last year, ENSC shows a very strong growth in Revenue. The Revenue has grown by 413.95%.
ENSC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.86% yearly.
EPS 1Y (TTM)91.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.06%
Revenue 1Y (TTM)413.95%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%654.13%

3.2 Future

Based on estimates for the next years, ENSC will show a very strong growth in Earnings Per Share. The EPS will grow by 41.95% on average per year.
Based on estimates for the next years, ENSC will show a very strong growth in Revenue. The Revenue will grow by 176.07% on average per year.
EPS Next Y68.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-33.73%
Revenue Next 2Y210.46%
Revenue Next 3Y176.07%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ENSC Yearly Revenue VS EstimatesENSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ENSC Yearly EPS VS EstimatesENSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1K -2K -3K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 12.42 indicates a correct valuation of ENSC.
ENSC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ENSC is cheaper than 96.64% of the companies in the same industry.
ENSC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 12.42
ENSC Price Earnings VS Forward Price EarningsENSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENSC Per share dataENSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

ENSC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ENSC's earnings are expected to grow with 41.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.95%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENSC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (10/14/2025, 8:00:02 PM)

After market: 2.48 +0.01 (+0.4%)

2.47

+0.15 (+6.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10
Inst Owners3.2%
Inst Owner Change0%
Ins Owners0.35%
Ins Owner Change0%
Market Cap7.34M
Analysts82.86
Price Target26.75 (983%)
Short Float %8.36%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.58%
Min EPS beat(2)34.36%
Max EPS beat(2)54.8%
EPS beat(4)3
Avg EPS beat(4)52.12%
Min EPS beat(4)-3.95%
Max EPS beat(4)123.26%
EPS beat(8)6
Avg EPS beat(8)32.27%
EPS beat(12)10
Avg EPS beat(12)41.51%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.42
P/S 0.99
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 2.16
EV/EBITDA N/A
EPS(TTM)-4.03
EYN/A
EPS(NY)0.2
Fwd EY8.05%
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS2.5
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -118.07%
ROE -194.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.1
Quick Ratio 2.1
Altman-Z -33.58
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.06%
EPS Next Y68.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)413.95%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%654.13%
Revenue Next Year-33.73%
Revenue Next 2Y210.46%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y31.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y62.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.95%
OCF growth 3YN/A
OCF growth 5YN/A